<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04345835</url>
  </required_header>
  <id_info>
    <org_study_id>RS/19.20</org_study_id>
    <nct_id>NCT04345835</nct_id>
  </id_info>
  <brief_title>Prone Flexed Position in Percutanous Nephrolithotomy</brief_title>
  <official_title>Prone Flexed Position in Percutanous Nephrolithotomy in Comparsion With Standard Prone Position. A Randomized Controlled Trial.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kafrelsheikh University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kafrelsheikh University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      prone flexed position in percutanous nephrolithotomy in comparsion with standard prone&#xD;
      position. A randomized controlled trial.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients meeting the inclusion criteria will be randomly allocated to 2 groups:&#xD;
&#xD;
        1. 1st group will undergo prone-flexed PCNL.&#xD;
&#xD;
        2. 2nd group will undergo prone PCNL.&#xD;
&#xD;
      III. Recruitment of participants Patients appointed for an outpatient diagnostic cystoscopy&#xD;
      will be reviewed for the inclusion and exclusion criteria. Legible patients will be asked to&#xD;
      participate in the study and to sign the informed consent form.&#xD;
&#xD;
      IV. Randomisation Randomization will be performed using computer generated random tables&#xD;
      using stratified blocked randomization in 1:1 ratio.&#xD;
&#xD;
      V. Study procedure Preoperative evaluations included&#xD;
&#xD;
        1. Detailed medical history&#xD;
&#xD;
        2. Physical examination&#xD;
&#xD;
        3. Routine blood examination&#xD;
&#xD;
        4. Urinalysis &amp; urine cytology&#xD;
&#xD;
        5. Renal and liver function tests&#xD;
&#xD;
        6. Coagulation profile&#xD;
&#xD;
      8. Computed tomography of the abdomen and pelvis&#xD;
&#xD;
      Operative Technique&#xD;
&#xD;
      Prone-flexed positioning i. Retrograde access will be obtained ii. The patient is&#xD;
      repositioned prone with adequate padding under the pressure points of the head, chest, knees,&#xD;
      and feet.&#xD;
&#xD;
      iii. The table is flexed 30 degrees at the level of the patient's mid lumbar region to open&#xD;
      the space between the 12th rib and the posterior iliac crest dropping the gluteal muscles&#xD;
      from the working plane.&#xD;
&#xD;
      Ancillary intervention&#xD;
&#xD;
      Patients will receive a 20-mL infiltration of 0.25% bupivacaine. Under fluoroscopic guidance,&#xD;
      the local analgesic was infiltrated with a 22-gauge spinal needle (10-cm length) along the&#xD;
      nephrostomy tract at the 3, 6, 9, and 12 o'clock positions (5 mL in each tract), including&#xD;
      the muscles, subcutaneous tissue, and skin.&#xD;
&#xD;
      Patients will receive 1 g tranexamic acid at induction followed by three further doses of 500&#xD;
      mg over the next 24 h.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 1, 2018</start_date>
  <completion_date type="Actual">April 1, 2020</completion_date>
  <primary_completion_date type="Actual">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Care Provider)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>position complications</measure>
    <time_frame>end of the study</time_frame>
    <description>Comparing the prone with the prone-flexed position for PCNL reporting complications using the Clavien-Dindo system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>stone score system</measure>
    <time_frame>end of the study</time_frame>
    <description>Comparison of the Guy's (19)&quot; combines the number of stones, their location, and abnormal patient anatomy into a score 1-4&quot;, S.T.O.N.E. (20)&quot;uses the stone size, tract length, obstruction, number of calyces involved, and stone density from patient's preoperative CT scan&quot;, and CROES (21) &quot;a continuous variable calculated by stone characteristics, patient data, and surgeon/centre experience&quot; Scores for predicting outcomes following PCNL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stone characteristics</measure>
    <time_frame>end of the study</time_frame>
    <description>Explore the relationship between stone density using various HU values &quot;highest HU value (HUmax), lowest HU value (HUmin) and average HU value (HUave)&quot;on and outcomes of percutaneous nephrolithotomy (PCNL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>stone volume</measure>
    <time_frame>end of the study</time_frame>
    <description>Assess the impact of the ellipsoid volume of the stone [volume = Ï€/6*(AP*H*CC)] after measuring the antero-posterior and horizontal dimensions in the axial images and the cranio-caudal dimension in the coronal images on and outcomes of percutaneous nephrolithotomy (PCNL).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hemostatic measures</measure>
    <time_frame>end of the study</time_frame>
    <description>Investigate the effect of antifibrinolytic tranexamic acid usage on blood loss during PCNL.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">300</enrollment>
  <condition>Renal Stones</condition>
  <arm_group>
    <arm_group_label>prone flexed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>prone flexed PCNL position</description>
  </arm_group>
  <arm_group>
    <arm_group_label>prone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>prone position PCNL</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutanous nephrolithotomy (PCNL)</intervention_name>
    <description>different procedure positioning</description>
    <arm_group_label>prone</arm_group_label>
    <arm_group_label>prone flexed</arm_group_label>
    <other_name>PNL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Large renal or upper ureteral calculi or both,&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  (1) Age &lt;18 years or Pregnancy (2) Ureter pelvic junction obstruction (3) Bilateral&#xD;
             simultaneous PCNL (4) Need for 3 percutaneous tracts intraoperative (5) Morbid obesity&#xD;
             (BMI &gt;40) (6) Non opaque renal stones. (7)Refuse to complete study requirements&#xD;
             (8)Untreated UTI (9)Atypical bowel interposition by CT (10)Tumour in the presumptive&#xD;
             access tract area or Potential malignant kidney tumour&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Diaa Eldin Taha, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lecturer of urology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kafrelsheikh faculty of medicine</name>
      <address>
        <city>Kafr Ash Shaykh</city>
        <state>Kafrelsheikh</state>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 12, 2020</study_first_submitted>
  <study_first_submitted_qc>April 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 14, 2020</study_first_posted>
  <last_update_submitted>April 13, 2020</last_update_submitted>
  <last_update_submitted_qc>April 13, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 15, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kafrelsheikh University</investigator_affiliation>
    <investigator_full_name>Diaa Eldin Taha Ramadan Mohamed</investigator_full_name>
    <investigator_title>Lecturer of urology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Calculi</mesh_term>
    <mesh_term>Nephrolithiasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

